BlackRock Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

BlackRock Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$31.9M	Buy	384,886 +25,913	+7%	+$2.23M	0.03%	399
2016 Q3	$33.2M	Buy	358,973 +2,312	+0.6%	+$218K	0.03%	384
2016 Q2	$27.7M	Sell	356,661 -134,298	-27%	-$11.4M	0.03%	429
2016 Q1	$40.5M	Buy	490,959 +18,995	+4%	+$1.55M	0.04%	363
2015 Q4	$49.4M	Buy	471,964 +56,337	+14%	+$5.88M	0.05%	324
2015 Q3	$43.8M	Sell	415,627 -125,722	-23%	-$16.8M	0.05%	323
2015 Q2	$74M	Sell	541,349 -264,747	-33%	-$32.8M	0.08%	249
2015 Q1	$100M	Sell	806,096 -249,623	-24%	-$26.4M	0.1%	213
2014 Q4	$95.4M	Sell	1,055,719 -171,041	-14%	-$14.2M	0.1%	222
2014 Q3	$88.5M	Buy	1,226,760 +168,148	+16%	+$11.1M	0.09%	234
2014 Q2	$65.9M	Sell	1,058,612 -155,936	-13%	-$9.42M	0.06%	290
2014 Q1	$82.8M	Buy	1,214,548 +315,926	+35%	+$23.3M	0.08%	254
2013 Q4	$63.2M	Sell	898,622 -24,919	-3%	-$1.69M	0.06%	306
2013 Q3	$66.7M	Buy	923,541 +432,235	+88%	+$28.7M	0.07%	286
2013 Q2	$27.4M	Buy	+491,306	New	+$30.6M	0.03%	443

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors's BMRN Position: Q4 2016 in Review

BlackRock Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 7.2% in Q4 2016, buying an estimated $2.23M and bringing the position to 384,886 shares worth $31.9M. The position accounts for 0.03% of the portfolio, ranked #399.

BlackRock Advisors first reported a position in BMRN in Q2 2013 and has held it in 15 quarters since. The position peaked at $100M in Q1 2015. 414 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

BlackRock Advisors held 384,886 shares of BioMarin Pharmaceuticals worth $31.9M as of Q4 2016.
BlackRock Advisors bought 25,913 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $2.23M.
BioMarin Pharmaceuticals made up 0.03% of BlackRock Advisors's portfolio in Q4 2016, its #399 holding.
BlackRock Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's BioMarin Pharmaceuticals position peaked at $100M in Q1 2015.
414 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.